microRNA-142 (miR-142)

microRNA-142 is a small, non-coding RNA molecule primarily expressed in hematopoietic cells. It has two mature isoforms (miR-142-3p, miR-142-5p) that arise from the same precursor but target different mRNAs. miR-142 regulates key aspects of immune cell lineage commitment and function, controls erythrocyte and megakaryocyte physiology, and balances intracellular signaling pathways (AKT, ERK, gp130/Ras/Cytokine pathway). It acts as a molecular switch in stem cell responses to differentiation cues and maintains Treg function by modulating cAMP and cGMP turnover. Dysregulation of miR-142 is implicated in cancer progression, hematological disease, and autoimmunity. Despite its importance, no approved therapies directly target miR-142, but experimental strategies are in development based on antisense oligonucleotides and modulation of its downstream effectors[1][3][4][5][6].

Other names

hsa-mir-142MIRN142mir-142MIR142miR-142-3pmiR-142-5p

Drugs targeting miR-142 typically act via: - Antisense oligonucleotide-mediated inhibition (preventing miR-142:mRNA binding) - Modulation of downstream targets (e.g., PDE3B inhibitors for autoimmune disease) - Synthetic miRNA mimics or antagonists to restore or suppress miR-142 function